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Introduction: Obesity is an unfavorable prognostic factor in breast cancer (BC) patients regardless of menopausal
status and treatment received. However, the association between obesity and survival outcome by pathological
subtype requires further clarification.
Methods: We performed a retrospective analysis including 5,683 operable BC patients enrolled in four randomized
clinical trials (GEICAM/9906, GEICAM/9805, GEICAM/2003–02, and BCIRG 001) evaluating anthracyclines and taxanes
as adjuvant treatments. Our primary aim was to assess the prognostic effect of body mass index (BMI) on disease
recurrence, breast cancer mortality (BCM), and overall mortality (OM). A secondary aim was to detect differences of
such prognostic effects by subtype.
Results: Multivariate survival analyses adjusting for age, tumor size, nodal status, menopausal status, surgery type,
histological grade, hormone receptor status, human epidermal growth factor receptor 2 (HER2) status,
chemotherapy regimen, and under-treatment showed that obese patients (BMI 30.0 to 34.9) had similar prognoses
to that of patients with a BMI < 25 (reference group) in terms of recurrence (Hazard Ratio [HR] = 1.08, 95% Confi-
dence Interval [CI] = 0.90 to 1.30), BCM (HR = 1.02, 0.81 to 1.29), and OM (HR = 0.97, 0.78 to 1.19). Patients with severe
obesity (BMI ≥ 35) had a significantly increased risk of recurrence (HR = 1.26, 1.00 to 1.59, P = 0.048), BCM (HR = 1.32,
1.00 to 1.74, P = 0.050), and OM (HR = 1.35, 1.06 to 1.71, P = 0.016) compared to our reference group. The prognostic
effect of severe obesity did not vary by subtype.
Conclusions: Severely obese patients treated with anthracyclines and taxanes present a worse prognosis regarding
recurrence, BCM, and OM than patients with BMI < 25. The magnitude of the harmful effect of BMI on survival-related
outcomes was similar across subtypes.* Correspondence: ealbac@uma.es
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Breast cancer (BC) is the most frequent invasive neo-
plasm in women. By 2015 the annual global incidence of
BC is estimated at 1.6 million women [1]. The incidence
in Europe alone will be over 450,000 new cases, resulting
in 138,000 deaths [1]. Among others, obesity is a risk
factor for several types of cancer, including BC [2], and
has recently gained special relevance due in part to the
dramatic increase in the prevalence of obesity observed
worldwide. In fact, if current trends continue, over 50% of
the world’s population will be obese by the year 2030 [3].
Recent cohort studies show that BC patients who are
obese at diagnosis exhibit worse outcomes than their
normal-weight counterparts in terms of probability of
recurrence, contralateral BC, second primary malignan-
cies, and overall mortality (OM) [4,5]. Whereas obese
women may be at risk for being diagnosed at a more ad-
vanced stage of disease than other women, multivariate
analyses confirm obesity as an independent prognostic
factor for risk of recurrence and survival [5]. Addition-
ally, recently published meta-analyses confirm a negative
effect of obesity on BC prognosis [5-8]. These data, how-
ever, are mostly based on cohort studies with several
limitations, such as sample heterogeneity regarding tumor
stage, treatment received, follow-up period, and the use of
self-reported height and weight data to calculate body
mass index (BMI).
The association between obesity and prognosis is also
explored in several clinical trials restricted to patients
with early-stage BC. These studies were in patients receiv-
ing different treatments (for example, hormone therapy,
chemotherapy protocols with/without anthracyclines) and
reported conflicting results [9-15]. Although most of these
studies showed an increased risk of death related to obes-
ity, in the modern era of adjuvant anthracyclines and tax-
anes the association between BMI and disease recurrence
and/or breast cancer mortality (BCM) requires further ex-
ploration together with an examination of the magnitude
of such associations by pathological subtype, that is es-
trogen receptor (ER)/progesterone receptor (PR)-posi-
tive/human epidermal growth factor-2 (HER2)-negative,
HER2-positive, triple-negative). The pooling of data from
all patients participating in four high-quality randomized
clinical trials with similar treatment and follow-up proto-
cols offers a unique opportunity to assess the influence of
BMI on clinical outcomes while minimizing unexplained
variability commonly found in observational studies. Thus,
the aim of this study was to assess the prognostic effect of
BMI on recurrence, breast cancer mortality (BCM), and
overall mortality (OM) among BC patients treated with ad-
juvant anthracyclines and taxanes, enrolled in four phase-
III Spanish Breast Cancer Research Group (GEICAM) and
Breast Cancer International Research Group (BCIRG)
clinical trials (GEICAM/9906, GEICAM/9805, GEICAM/2003–02, and BCIRG 001) [16-20]. We also evaluated the
prognostic role of obesity according to the different patho-
logical BC subtypes as defined by immunohistochemistry.
Methods
Study design and participants
The cohort is comprised of 98% Caucasian women
(reflecting the breast cancer patient population in Spain,
as most patients included in this pooled analyses were
from this country) from four randomized trials that eval-
uated systemic adjuvant chemotherapy (CT) based on
anthracyclines and taxanes for lymph node-negative and
lymph node-positive operable BC. These phase III trials
accrued patients between 1996 and 2008 and evaluated
the following CT protocols: 1) six cycles of docetaxel,
doxorubicin, and cyclophosphamide (TAC) or fluoroura-
cil, doxorubicin, and cyclophosphamide (FAC) for high-
risk node-negative patients (GEICAM/9805) [17]; 2) six
cycles of fluorouracil, epirubicin, and cyclophosphamide
(FEC) or four cycles of FEC followed by weekly pacli-
taxel for node-positive patients (GEICAM/9906) [16]; 3)
six cycles of TAC or FAC for node-positive patients
(BCIRG 001) [18,19]; and 4) six cycles of FAC or four
cycles of FAC followed by weekly paclitaxel for node-
negative patients (GEICAM/2003-02) [20]. Chemotherapy
was prescribed by actual body weight and was adjusted for
obese patients in about 2% of patients (151 of 5,683 pa-
tients). After completing the CT treatment, tamoxifen,
aromatase inhibitors, or the switching strategy (that is,
tamoxifen followed by aromatase inhibitor) were adminis-
tered for five years to patients with ER-positive and/or PR-
positive tumors. Radiotherapy (RT) was mandatory after
breast-conserving surgery and was administered after
mastectomy, according to each institution’s guidelines.
These trials were conducted before the approval of adju-
vant trastuzumab therapy. Further details of the trial de-
signs and findings have been reported elsewhere [16-20].
The Institutional Review Boards at the study sites ap-
proved these trials (see Additional file 1 for a list), and
the participants provided written informed consent prior
to randomization. For this analysis, we excluded patients
who were randomized but not included in the corre-
sponding trial (32 patients) and those who had incom-
plete height or weight data (9 women). The final cohort
consisted of 5,683 patients.
Procedure
The independent variable of interest, BMI, was calcu-
lated based on the height and weight of each participant
at the start of the study. According to the World Health
Organization definition, patients were classified into five
BMI subgroups: underweight (<18.5 kg/m2), normal weight
(18.5 to 24.9 kg/m2), overweight (25.0 to 29.9 kg/m2),
obese (30.0 to 34.9 kg/m2) and severely obese (≥35.0 kg/m2)
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the first two groups were combined and, thus, BMI
<25 kg/m2 was used as the reference category. Other vari-
ables considered included: age, menopausal status, surgery
type, histology type, histological grade, tumor size, nodal
status, hormone receptor, and HER2 status. We included
the category, HER2 unknown, due to the high number of
participants with missing data in the GEICAM/9805
study. Regarding CT, the overall dose of each drug in the
corresponding regimen was compared with the theoretical
dose based on the patient’s estimated body weight using
the real weight of the patient at enrollment [22]. As in
other studies, we considered women who received a dose
lower than 85% of the standard dose as undertreated [23].
Undertreatment was computed considering the initial
dose (initial undertreatment) and the total amount of CT
received (overall undertreatment). Toxicity was graded ac-
cording to the National Cancer Institute Common Tox-
icity Criteria; we considered grade 3 and 4 adverse events
to be clinically relevant [24].
We calculated the impact of obesity on different end-
points. Recurrence was defined as local, regional, or dis-
tant disease recurrence or the diagnosis of a second
primary breast cancer, including contralateral breast tu-
mors. In situ tumors were not considered as recurrence.
BCM was defined as death due to BC, and overall mor-
tality was defined as death from any cause. To guarantee
the quality and homogeneity of the follow-up data all
analyses were restricted to the first 10 years after
recruitment.
Statistical analysis
The Kaplan-Meier method was used to estimate survival,
and the log-rank test was used to assess the possible dif-
ferences between subgroups. Cox proportional hazards
regression analysis was performed to assess the prognos-
tic effect of BMI on recurrence, BCM, and OM [25].
Basic models were adjusted for the clinical trial from
which data originated (study) - which also acted as a
proxy for nodal involvement - and treatment regimen.
Full models included additional adjustment for age,
menopausal status, tumor size, histological grade, hor-
mone receptor status, HER2 status, surgery type, and
overall undertreatment (yes/no) as potential confounders.
In addition, to explore the shape of the dose–response
curve for BMI without assuming a linear relationship, nat-
ural splines were used in the full model, including four
knots based on Harrell’s recommended percentiles,
namely 5%, 35%, 65%, and 95% [26]. Finally, to test the
consistency of the excess risk associated with higher BMI,
subgroup analyses were conducted to estimate the effect
of having BMI ≥35 compared to BMI <25 per category of
the following variables: clinical trial, age, menopausal sta-
tus, histological type, pathologic primary tumor size, nodalinvolvement, surgery type, hormone therapy (yes/no),
undertreatment (yes/no), and pathological subtype. We
report two-sided P-values, and P <0.05 was considered
statistically significant. Statistical analyses were performed
using STATA 12 (StataCorp LP, College Station, TX,
USA).
Results
The characteristics of the patients enrolled in each trial
are provided as additional material (see Additional file 2).
In total, 5,683 patients from four phase III trials with
complete height and weight data were analyzed in the
pooled data. The median follow-up time of patients who
were alive at the time of this analysis was 93.4 months
(range from 0.6 to 120). Table 1 describes sociodemo-
graphic and clinical characteristics of the sample and illus-
trates the relationship between patient characteristics and
BMI category. For the sole purpose of simplifying the
sample description here, we combined BMI into three cat-
egories. Using 30 kg/m2 as the cut off, 4,307 patients
(75.8%) were classified as non-obese (BMI <30), 945 pa-
tients (16.6%) had BMI between 30 and 34.9 (obese) and
431 patients (7.8%) had BMI greater than or equal to 35
(severely obese). The median age was 48 years in the non-
obese patients (range 42 to 56), 56 years among obese pa-
tients (range 49 to 62) and 55 years among the severely
obese (range 49 to 62). Severely obese patients were more
likely to be postmenopausal, to present lymph node posi-
tivity, and to be undertreated compared to non-obese pa-
tients. Additionally, severely obese patients were less likely
to present with a tumor size <2 cm, undifferentiated tu-
mors, or HER2-positive tumors. Even though the preva-
lence of undertreatment was low, as expected in clinical
trials, there were significant differences in the doses (cal-
culated as mg/m2) of CT between severely obese patients
and non-obese patients. A higher proportion of severely
obese patients received doses below 85% of the theoretical
dose of CT compared with the non-obese patients (6.0%
versus 2.4% in the first dose and 15.0% versus 7.1% con-
sidering the cumulative dose, P <0.001). Patients with se-
vere obesity were as likely to present with severe adverse
events (grades 3 to 4) as non-obese patients (42.0% versus
40.4%, P = 0.498).
To illustrate the relationship between BMI and survival,
we calculated crude Kaplan-Meier curves for recurrence-
free survival, breast cancer survival and overall survival
for each BMI category (Figure 1). In the Cox regression
basic model (Table 2), obese patients’ outcomes were not
significantly different from those of the reference group
(BMI18.5 to 24.9), in terms of recurrence (Hazard Ratio
[HR] 0.98, 95% CI 0.82, 1.17, P = 0.831), BCM (HR 1.04,
95% CI 0.83, 1.29, P = 0.757), or OM (HR 1.07, 95% CI
0.87, 1.3, P = 0.526). However, patients with severe obesity
presented significantly worse outcomes in terms of BCM
Table 1 Distribution of variables by BMI category (non-obese, obese, and severely obese women)
BMI <30.0 BMI 30 to 34.9 BMI ≥ 35.0
Number (%) Number (%) Number (%) P-valuea
Age at diagnosis, years <0.001
20 to 44 1,473 (34.2%) 138 (14.6%) 56 (13.0%)
45 to 54 1,599 (37.1%) 284 (30.1%) 153 (35.5%)
55 to 64 932 (21.6%) 364 (38.5%) 147 (34.1%)
65 to 76 303 (7.0%) 159 (16.8%) 75 (17.4%)
Median (percentiles 25 to 75) 48 (42 to 56) 56 (49 to 62) 55 (49 to 62)
Menopausal status <0.001
Postmenopausal 1,737 (40.3%) 631 (66.8%) 293 (68.0%)
Premenopausal 2,570 (59.7%) 314 (33.2%) 138 (32.0%)
Histology 0.730
Ductal 3,645 (84.6%) 788 (83.4%) 376 (87.2%)
Lobulillar 385 (8.9%) 93 (9.8%) 32 (7.4%)
Mixed 46 (1.1%) 12 (1.3%) 4 (0.9%)
Others 230 (5.3%) 52 (5.5%) 19 (4.4%)
Unknown 1 (0.0%) 0 (0.0%) 0 (0.0%)
Histological grade 0.054
1 384 (8.9%) 81 (8.6%) 34 (7.9%)
2 1,792 (41.6%) 416 (44.0%) 196 (45.5%)
3 1,823 (42.3%) 381 (40.3%) 187 (43.4%)
Unknown 308 (7.1%) 67 (7.1%) 14 (3.2%)
Pathologic primary tumor size <0.001
T1 2,192 (50.9%) 423 (44.8%) 179 (41.5%)
T2 1,948 (45.2%) 485 (51.3%) 232 (53.8%)
T3 167 (3.9%) 37 (3.9%) 20 (4.6%)
Nodes 0.021
Negative 2,278 (52.9%) 487 (51.5%) 198 (45.9%)
Positive 2,029 (47.1%) 458 (48.5%) 233 (54.1%)
Estrogen receptor 0.647
Negative 1,398 (32.5%) 321 (34.0%) 137 (31.8%)
Positive 2,899 (67.3%) 623 (65.9%) 291 (67.5%)
Unknown 10 (0.2%) 1 (0.1%) 3 (0.7%)
Progesterone receptor 0.199
Negative 1,654 (38.4%) 373 (39.5%) 149 (34.6%)
Positive 2,576 (59.8%) 558 (59.0%) 276 (64.0%)
Unknown 77 (1.8%) 14 (1.5%) 6 (1.4%)
Human epidermal growth factor-2 status 0.030
Negative 3,036 (70.5%) 690 (73.0%) 329 (76.3%)
Positive 656 (15.2%) 123 (13.0%) 51 (11.8%)
Unknown 615 (14.3%) 132 (14.0%) 51 (11.8%)
Type of surgery 0.071
Mastectomy 2,021 (46.9%) 405 (42.9%) 195 (45.2%)
Conservative 2,286 (53.1%) 540 (57.1%) 236 (54.8%)
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Table 1 Distribution of variables by BMI category (non-obese, obese, and severely obese women) (Continued)
Hormonotherapy 0.334
None 1,068 (24.8%) 256 (27.1%) 115 (26.7%)
Yes 3,081 (71.5%) 664 (70.3%) 300 (69.6%)
Unknown 158 (3.7%) 25 (2.6%) 16 (3.7%)
Adverse events (grades 3,4) 0.498
No 2,565 (59.6%) 578 (61.2%) 250 (58.0%)
Yes 1,742 (40.4%) 367 (38.8%) 181 (42.0%)
Initial under-treatment (in the first dose)b <0.001
No 4,205 (97.6%) 922 (97.6%) 405 (94.0%)
Yes 102 (2.4%) 23 (2.4%) 26 (6.0%)
Per type of treatmentc
Epirubicin <85% 5 (0.5%) 5 (2.3%) 4 (4.0%) 0.002
Cyclophosphamide <85% 12 (0.3%) 4 (0.4%) 8 (1.9%) <0.001
Fluorouracil <85% 8 (0.2%) 4 (0.5%) 7 (2.2%) <0.001
Doxorubicin <85% 4 (0.1%) 3 (0.4%) 7 (2.1%) <0.001
Docetaxel <85% 24 (2.5%) 5 (2.4%) 6 (5.4%) 0.199
Paclitaxel <85% 62 (5.2%) 11 (4.2%) 7 (6.7%) 0.604
Overall undertreatmentb <0.001
No 3,903 (90.6%) 820 (86.8%) 360 (83.5%)
Yes 404 (9.4%) 125 (13.2%) 71 (16.5%)
Per type of treatment c
Epirubicin <85% 50 (5.5%) 15 (6.8%) 13 (13.1%) 0.011
Cyclophosphamide <85% 213 (4.9%) 49 (5.2%) 34 (7.9%) 0.032
Fluorouracil <85% 132 (3.9%) 25 (3.4%) 24 (7.5%) 0.005
Doxorubicin <85% 160 (4.7%) 40 (5.5%) 26 (7.8%) 0.040
Docetaxel <85% 117 (15.8%) 39 (18.9%) 10 (9.9%) 0.068
Paclitaxel <85% 159 (13.3%) 59 (22.6%) 26 (25.0%) <0.001
aP-values computed excluding women without information in the corresponding variable; bdefined as total dose received lower than 85% of the theoretical dose
prescribed; cpercentages including only women receiving the corresponding type of treatment. BMI, body mass index.
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95% CI 1.16, 1.85, P = 0.001). Differences in recurrence
did not attain statistical significance (HR 1.14, 95% CI
0.91, 1.42, P = 0.249) (Table 2 and Figure 1). Initial under-
treatment was not related to any of the endpoints of inter-
est, and was not considered in subsequent analyses.
In fully-adjusted models (Table 3), compared to the
reference group (BMI 18.5 to 24.9) obesity remained a
non-significant prognostic factor, but severe obesity in-
dependently increased the risk of recurrence (HR 1.25,
95% CI 0.99, 1.57, P = 0.052), BCM (HR 1.32, 95% CI
1.00, 1.74, P = 0.053), and OM (HR 1.35, 95% CI 1.06,
1.72, P = 0.016).
Figure 2 depicts the fully-adjusted HR dose–response
curve (dark line) and upper and lower limits of the CI
(lighter lines) for BMI for each of the three endpoints
of interest. For OM, the dose–response curve showedhigher HRs at both BMI extremes, but the 95% CIs did
not include the one only at the right end of the curve,
that is, for BMI ≥35. BCM and recurrence results also
indicated a positive dose–response relationship, but the
trend was not as pronounced and failed to reach statis-
tical significance.
Figure 3 presents the HR and 95% CIs associated with
severe obesity (BMI ≥35) for each survival outcome by
the categories of each covariate, considering the different
pathological BC subtypes. For these analyses, in order to
increase our statistical power, BMI <25 was considered
the reference category. These HR values were adjusted
for the rest of the variables included in the full model.
No statistically significant differences in the effect of
severe obesity were observed per category of the other
explanatory variables, but the effect seemed to be
more pronounced in younger women (age <45 years).
Figure 1 Crude Kaplan-Meier curves for each survival outcome for each body mass index (BMI) category. (A) Overall survival. The lower
curve shows patients with BMI ≥35. Overall log-rank P = 0.002; log-rank comparing the curve for BMI ≥35 with the rest was <0.001. (B) Breast
cancer survival. The lower curve shows patients with BMI ≥35. Overall log-rank P= 0.052; log-rank comparing the curve for BMI ≥35 with the rest = 0.006.
(C) Recurrence-free survival. The lower curve shows patients with BMI ≥35. Overall log-rank P= 0.226; log-rank comparing the curve for BMI ≥35 with
the rest = 0.040.
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vere obesity on survival outcomes was similar across the
three BC subtypes (ER/PR-positive/HER2-negative, HER2-
positive, triple-negative).
Discussion
In this retrospective survival analysis of pooled data
from four large, well-conducted, randomized phase III
trials of adjuvant CT, severe obesity (BMI ≥35) was sig-
nificantly associated with worse survival outcomes (OM
and BCM) and a higher risk of disease recurrence. Add-
itionally, the magnitude of the negative effect of BMI on
survival was similar across pathological subtypes (ER/PR-
positive/HER2-negative, HER2-positive, triple-negative).
However, obese patients (BMI 30.0 to 34.9) displayed
similar prognosis to patients with BMI below 25.0, not un-
expected given that most studies of women participating
in clinical trials show a relatively modest effect of obesity
on prognosis compared with population-based studies. A
recent multi-analysis [8] concluded that there was a (non-statistically significant) tendency to report higher prog-
nostic effects of obesity in BC patients in observational
studies than in randomized controlled trials (RCTs). In
this regard, our study supports the harmful prognostic ef-
fect of severe obesity among operable BC patients treated
with the most up-to-date CT schedules based on anthra-
cyclines and taxanes.
To the best of our knowledge, this is the largest ana-
lysis of RCTs examining obesity as a prognostic factor in
operable BC patients treated with anthracyclines and
taxanes, and adjusting for hormone receptor and HER2
status. It is also the second study to confine significant
prognostic effects to severely obese patients, supporting
previous work by Dignam and colleagues [27]. In a study
conducted by Berclaz et al., data from 6,792 BC patients
randomized in seven trials of the International Breast
Cancer Study Group from 1978 to 1993 were analyzed
[9]. These trials included observation (no adjuvant ther-
apy), endocrine therapy (tamoxifen), or cyclophosphamide,
methotrexate and fluorouracil (CMF)-based CT. Their
Table 2 Multivariate Cox proportional hazards regression analysis of effect of BMI and each study variable on overall
mortality, breast cancer mortality, and recurrence in basic models (adjusted for study and treatment regimen only)
Overall mortality Breast cancer mortality Recurrence
Variable Number Events HRa 95% CI P-value Events HR 95% CI P-value Events HR 95% CI P-value
Body mass
index, k/m2
<18.5 66 11 1.08 0.59, 1.98 0.796 9 1.06 0.54, 2.06 0.864 12 0.88 0.49, 1.56 0.650
18.5 to 24.9 2,297 312 1.00 256 1.00 419 1.00
25.0 to 29.9 1,944 265 0.99 0.84, 1.16 0.880 220 1.00 0.83, 1.20 0.984 348 0.95 0.83, 1.10 0.522
30.0 to 34.9 945 139 1.07 0.87, 1.30 0.526 111 1.04 0.83, 1.29 0.757 173 0.98 0.82, 1.17 0.831
≥35.0 431 91 1.47 1.16, 1.85 0.001 68 1.32 1.01, 1.72 0.043 95 1.14 0.91, 1.42 0.249
P for trend 0.002 P for trend 0.074 P for trend 0.287
Age at diagnosis,
years
23 to 44 1,667 276 1.00 245 1.00 416 1.00
45 to 54 2,036 228 0.66 0.55, 0.78 <0.001 187 0.61 0.50, 0.73 <0.001 296 0.54 0.47. 0.63 <0.001
55 to 64 1,443 202 0.92 0.77, 1.11 0.380 156 0.81 0.66, 0.99 0.036 231 0.66 0.56, 0.78 <0.001
65 to 76 537 112 1.41 1.13, 1.76 0.002 76 1.08 0.83, 1.39 0.583 104 0.81 0.65, 1.00 0.049
P for trend 0.030 P for trend 0.655 P for trend <0.001
Menopausal status
Postmenopausal 2,661 421 1.00 322 1.00 461 1.00
Premenopausal 3022 397 0.75 0.66, 0.86 <0.001 342 0.85 0.73, 0.98 0.031 586 1.05 0.93, 1.19 0.415
Histology
Ductal 4,809 700 1.00 571 1.00 892 1.00
Lobular 510 66 0.79 0.62, 1.02 0.072 52 0.76 0.57, 1.01 0.062 96 0.92 0.75, 1.14 0.446
Mixed 364 52 0.92 0.69, 1.22 0.561 41 0.89 0.65, 1.22 0.456 59 0.82 0.63, 1.07 0.150
Others 389 66 2.32 1.54, 3.49 <0.001 55 2.92 1.79, 4.75 <0.001 87 2.01 1.44, 2.83 0.000
Histological grade
1 499 35 1.00 23 1.00 55 1.00
2 2,404 277 2.09 1.47, 2.97 <0.001 217 2.51 1.63, 3.87 <0.001 382 1.84 1.39, 2.45 <0.001
3 2,391 440 3.70 2.62, 5.23 <0.001 369 4.77 3.13, 7.28 <0.001 523 2.82 2.13, 3.72 <0.001
Unknown 389 66 2.32 1.54, 3.49 <0.001 55 2.92 1.79, 4.75 <0.001 87 2.01 1.44, 2.83 <0.001
Pathologic primary tumor size
T1 2,794 249 1.00 194 1.00 349 1.00
T2 2,665 510 1.96 1.68, 2.28 <0.001 417 2.03 1.71, 2.41 <0.001 628 1.78 1.57, 2.04 <0.001
T3 224 59 2.14 1.61, 2.84 <0.001 53 2.39 1.76, 3.25 <0.001 70 1.98 1.53, 2.57 <0.001
P for trend <0.001 P for trend <0.001 P for trend <0.001
Estrogen receptor/
progesterone receptor
Both negative 1,502 300 1.00 256 1.00 349 1.00
Any of them positive 4,132 503 0.49 0.43, 0.57 <0.001 394 0.45 0.38, 0.53 <0.001 679 0.59 0.51, 0.67 <0.001
Unknown 49 15 0.77 0.46, 1.31 0.338 14 0.82 0.48, 1.41 0.471 19 1.00 0.63, 1.59 0.998
Human epidermal
growth factor-2 status
Negative 4,055 518 1.00 407 1.00 660 1.00
Positive 830 182 1.34 1.13, 1.59 0.001 153 1.42 1.18, 1.71 <0.001 223 1.38 1.18, 1.61 <0.001
Unknown 798 118 1.04 0.85, 1.28 0.690 104 1.17 0.94, 1 · 45 0.172 164 1.14 0.95, 1.36 0.157
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Table 2 Multivariate Cox proportional hazards regression analysis of effect of BMI and each study variable on overall
mortality, breast cancer mortality, and recurrence in basic models (adjusted for study and treatment regimen only)
(Continued)
Type of surgery
Mastectomy 2,621 512 1.00 420 1.00 633 1.00
Conservative 3,062 306 0.71 0.61, 0.82 <0.001 244 0.71 0.60, 0.83 <0.001 414 0.73 0.65, 0.83 <0.001
Hormonotherapy
No 1,439 314 1.00 263 1.00 354 1.00
Yes 4,045 451 0.42 0.36, 0.48 <0.001 356 0.39 0.33, 0.46 <0.001 622 0.51 0.45, 0.58 <0.001
Unknown 199 53 0.79 0.58, 1.06 0.112 45 0.77 0.56, 1.07 0.120 71 1.05 0.81, 1.37 0.692
Initial undertreatment
(first dose <85%)
No 5,532 648 1.00
Yes 151 16 1.01 0.78,1.31 0.932 16 1.06 0.64, 1.75 0.820 20 0.84 0.54, 1.31 0.447
Overall undertreatment
(dose <85%)
None 5,083 725 1.00 599 1.00 943 1.00
Epirubicine <85% 78 24 1.55 1.02, 2.36 0.040 20 1.56 0.98, 2.47 0.059 25 1.29 0.86, 1.93 0.226
Cyclophosphamide <85% 296 56 1.28 0.98, 1.69 0.074 41 1.13 0.82, 1.56 0.446 63 1.14 0.88, 1.47 0.323
Fluorouracil <85% 181 33 1.20 0.84, 1.70 0.316 23 1.01 0.66, 1.53 0.977 34 0.98 0.69, 1.38 0.888
Doxorubicin <85% 226 38 1.30 0.93, 1.81 0.119 27 1.12 0.76, 1.65 0.576 42 1.13 0.82, 1.54 0.451
Docetaxel <85% 176 32 1.08 0.74, 1.57 0.696 24 0.96 0.62, 1.47 0.846 39 1.04 0.74, 1.46 0.814
Paclitaxel <85% 244 27 1.43 0.94, 2.18 0.092 16 1.05 0.62, 1.78 0.863 30 1.09 0.74, 1.61 0.662
aHazard ratio, 95% CI and P-value adjusted for study and treatment regimen.
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http://breast-cancer-research.com/content/15/6/R105results showed that BMI independently predicted OM
(P = 0.03) but not risk of recurrence (P = 0.12). Azambuja
et al. analyzed 2,887 node-positive BC patients included
in the BIG 02–98 trial who were treated with a CT regi-
men based on anthracyclines. In this study, obesity
emerged as an independent unfavorable prognostic factor
for OM (P = 0.008) and recurrence (P = 0.04) [11]. A
retrospective analysis of 4,077 women from the National
Surgical Adjuvant Breast and Bowel Project clinical trials
with ER-negative, node-negative BC, treated with several
CT regimens with or without anthracyclines, showed
higher mortality only among severely obese patients but
not among obese patients [27]. Also our results are con-
sistent with those obtained by Sparano et al. in the ECOG
1199 study [12] in which there was also a correlation be-
tween increased BMI and poorer disease-free survival and
overall survival. However, in our study the correlation be-
tween BMI >35 and worse prognosis was observed in all
pathological subtypes, whereas in the ECOG 1199 this ef-
fect seemed to be limited to ER-positive patients. These dif-
ferences may be due to a different definition of ER-positive
status (>10% in ECOG 1199 versus >1% in our studies).
Furthermore, the percentage of obese patients was lower in
our study (16.6 versus 36.6% respectively) and we did not
include black patients. This is relevant because the ECOG1199 has shown a significant association between black
race, increased frequency of obesity and a worse prognosis
in ER-positive patients [28].
Certain characteristics of our study may explain the dif-
ferences between our results and previous work. First, the
homogeneity of our sample, which included only patients
with low comorbidity, could partially explain the stronger
prognostic role of obesity observed in population-based
studies than in our study. Such differences in effect may be
attributed to other conditions such as diabetes, metabolic
syndrome, and other chronic diseases that are associated
both with obesity and with poorer prognoses. Because of
the criteria used in clinical trials, obese patients with im-
paired health due to these conditions have a lower prob-
ability of being included in a clinical trial. Second, the
assessment necessary to establish patient eligibility for a
clinical trial may result in more accurate staging and con-
sequently less confounding between obesity and delayed
diagnosis often observed in obese women. Third, our re-
sults are based on a large sample size of more than 5,600
patients. Pooled analyses have shown that risk estimates
based on retrospective analysis of clinical trials often de-
cline as the sample size increases [9-11]. Finally, all our
patients were treated homogeneously with anthracycline-
based CT, such an effective treatment that it may have
Table 3 Summary of multivariate Cox proportional hazards regression analysis of effect of BMI and each study
variable on overall mortality, breast cancer mortality, and recurrence in full models
Overall mortality Breast cancer mortality Recurrence
Variable HRa 95% CI P-value HR 95% CI P-value HR 95% CI P-value
Body mass index, k/m2
<18.5 0.98 0.53, 1.79 0.945 0.95 0.48, 1.85 0.871 0.77 0.43, 1.37 0.377
18.5 to 24.9 1.00 1.00 1.00
25.0 to 29.9 0.95 0.80, 1.12 0.549 1.01 0.84, 1.22 0.905 1.03 0.89, 1.19 0.728
30.0 to 34.9 0.98 0.79, 1.20 0.814 1.02 0.81, 1.29 0.860 1.07 0.89, 1.29 0.460
≥35 1.35 1.06, 1.72 0.016 1.32 1.00, 1.74 0.053 1.25 0.99, 1.57 0.052
Age
Per 5 years 0.92 0.87, 0.97 0.003 0.86 0.81, 0.92 <0.001 0.84 0. 80, 0.89 <0.001
Menopausal status
Postmenopausal 1.00 1.00 1.00
Premenopausal 0.60 0.48, 0.74 <0.001 0.56 0.44, 0.71 <0.001 0.64 0.53, 0.77 <0.001
Pathologic primary tumor size
T1 1.00 1.00 1.00
T2 1.82 1.56, 2.32 <0.001 1.87 1.57, 2.22 <0.001 1.67 1.46, 1.91 <0.001
T3 1.88 1.40, 2.53 <0.001 2.07 1.51, 2.84 <0.001 1.71 1.31, 2.23 <0.001
Histological grade
1 1.00 1.00 1.00
2, 3, or unknown 1.26 1.07, 1.48 0.006 1.32 1.10, 1.58 0.003 1.24 1.07, 1.43 0.004
Type of surgery
Mastectomy 1.00 1.00 1.00
Conservative 0.82 0.70, 0.95 0.008 0.83 0.70, 0.98 0.028 0.84 0.74, 0.96 0.011
Estrogen receptor/progesterone
receptor
Both negative 1.00 1.00 1.00
Any positive 0.56 0.48, 0.64 <0.001 0.51 0.44, 0.60 <0.001 0.66 0.57, 0.75 <0.001
Unknown 0.85 0.51, 1.44 0.558 0.89 0.52, 1.54 0.689 1.10 0.69, 1.75 0.699
Human epidermal growth
factor-2 status
Negative 1.00 1.00 1.00
Positive 1.19 1.00, 1.42 0.048 1.23 1.01, 1.49 0.037 1.23 1.05, 1.44 0.009
Unknown 1.00 0.82, 1.23 0.965 1.11 0.89, 1.38 0.361 1.09 0.91, 1.30 0.335
Undertreatment
None 1.00 1.00 1.00
Epirubicine <85% 2.36 1.18, 4.72 0.015 3.06 1.47, 6.36 0.003 1.84 0.93, 3.63 0.078
Cyclophosph <85% 0.86 0.35, 2.13 0.74 0.93 0.34, 2.53 0.880 1.31 0.58, 2.95 0.519
Fluorouracil <85% 0.64 0.30, 1.34 0.235 0.45 0.19, 1.07 0.069 0.50 0.26, 0.99 0.046
Doxorubicin <85% 1.86 0.89, 3.88 0.097 1.86 0.82, 4.22 0.134 1.29 0.63, 2.64 0.478
Docetaxel <85% 0.84 0.46, 1.53 0.559 0.70 0.35, 1.40 0.315 0.75 0.44, 1.28 0.294
Paclitaxel <85% 1.37 0.90, 2.09 0.147 1.06 0.62, 1.81 0.824 1.15 0.78, 1.70 0.491
Models were adjusted for all the other variables in the table. aHazard ratio, 95% CI and P-value adjusted for study, treatment regimen and the rest of variables in
the table.
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Figure 2 Hazard ratio dose–response curve (dark line) and upper and lower limits of the confidence interval (lighter lines) for body
mass index for each survival outcome. (A) Overall Mortality. (B) Breast cancer mortality. (C) Recurrence. Estimates were adjusted for all the
variables in the full model.
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http://breast-cancer-research.com/content/15/6/R105partly counteracted the adverse prognostic effect of obesity
when compared to the obesity effect found in population
and cohort studies, or even in clinical trials with suboptimal
CT schedules like CMF. It should also be anticipated that
undertreatment is less frequent when patients are treated
within the context of a clinical trial.
In fact, undertreatment may also contribute to poorer
survival rates in obese BC patients [22,29]. Several stud-
ies have shown that obese BC patients are more likely to
receive reduced doses of CT compared to normal-weight
women [22,29,30]. Obese patients treated with CMF-
based CT were significantly more likely to receive a
lower CT dose for the first course (<85% of expected
dose) than those with normal or intermediate BMI
values (39% versus 16%, P <0.0001) and this undertreat-
ment was associated with a significantly worse outcome
for ER-negative patients [27]. However, several studies
found that obese women receiving full doses of CT did
not experience more toxicity than normal-weight pa-
tients [22,30,31]. In our study, although undertreatment
was generally low, severely obese patients were alsomore likely to be undertreated, despite the prevalence of
serious adverse events being similar to that observed in
non-obese patients. Even in the context of a clinical trial,
severely obese patients were almost three times more
likely to receive suboptimal doses from the start, and
this insufficient dose was maintained in subsequent cy-
cles in more than 90% of cases. Oncologists should be
aware of the importance of prescribing full weight-based
doses in agreement with the recommendations of the
American Society of Clinical Oncology [22].
The pathways involved in the relationship between
obesity and BC outcomes remain unclear, but obesity is
known to affect several hormones and growth factors that
are potentially associated with BC [32]. Consequently,
obese patients may have elevated tumor cell proliferation
and metastasis due to undefined adipokine effects on
tumor cells [33]. For instance, hyperinsulinism has been
correlated with BMI, recurrence, and BCM, regardless of
hormone receptor status [34]. The pro-angiogenic and
pro-inflammatory adipokines such as leptin, IL6, TNF-α,
and vascular endothelial growth factor (VEGF), secreted
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Figure 3 Hazard ratios and 95% CI associated with severe obesity (body mass index ≥35) compared to the reference group (body
mass index <25) for each survival outcome by the categories of each covariate. (A) Overall mortality. (B) Breast cancer mortality. (C)
Recurrence estimates were adjusted for all the variables in the full model. The size of the interval and the box are proportional to the amount of
information available per stratum. GEICAM, Spanish Breast Cancer Research Group; BCIRG, Breast Cancer International Research Group; pT,
pathologic primary tumor size; surg, surgery; HER2: human epidermal growth factor-2; ER, estrogen receptor; PR, progesterone receptor.
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http://breast-cancer-research.com/content/15/6/R105by fat tissue, are commonly elevated in obese patients
[35,36]. As BMI is directly related to circulating estrogen
levels, the production of estrogens by adipose tissue has
also been postulated as a factor in the more biologically
aggressive ER-positive tumors in postmenopausal women
[37]. Also higher rates of angiolymphatic invasion among
obese women with breast cancer may contribute to their
poorer outcomes, as described by Gillespie et al. in their
retrospective series [38].Several studies have evaluated the role of obesity as a
risk factor for BC development according to different
BC subtypes [39-42]. However, data on the role of obes-
ity on patient prognosis according to these subtypes
are scarce. A recent meta-analysis found no evidence
of the prognostic role of obesity varying by hormone
receptor status [7], although HER2 receptor data were
not available until recently. In fact, a study on 4,770
operable BC patients treated with a CT regimen based
Pajares et al. Breast Cancer Research 2013, 15:R105 Page 12 of 14
http://breast-cancer-research.com/content/15/6/R105on anthracyclines and taxanes reported a worse outcome
specifically in hormone receptor-positive/HER2-negative
disease patients, but not among patients with HER2-
positive or triple-negative disease [12]. In contrast, our
analyses failed to detect a difference in the observed
prognostic role of severe obesity by subtype.
Although the shortcomings of our study are not un-
common in retrospective analyses of clinical trials, our
results should be interpreted in the context of the study
limitations. BMI was measured only at the beginning of
follow up and further changes were not considered, in
part due to the difficulty in assessing changes influenced
by CT/hormone treatment side effects. For the analysis
by tumor subtype, hormone receptor positivity was
assessed in each trial under the available criteria at that
moment, and the lack of information on HER2 in the
GEICAM/9805 trial substantially decreases the statistical
power of the analyses. Major strengths of this study in-
clude a large sample size (n >5,600), precise BMI infor-
mation at baseline, and a standardized CT treatment
based on the most active drugs in the adjuvant setting
available at that time (anthracyclines and taxanes).
In summary, this study shows that obesity (BMI 30.0
to 34.9) is not associated with worse survival outcomes
in operable BC patients treated with anthracycline- and
taxane-based CT. Severely obese patients (BMI ≥35.0),
however, present an increased risk of recurrence, BCM,
and OM compared to patients with BMI <25.0. Further,
the magnitude of the negative effect of BMI on survival
outcomes was similar across pathological BC subtypes.
Conclusions
Based on a large retrospective analysis of four random-
ized clinical trials of operable BC patients treated with
anthracyclines and taxanes, and adjusting for hormone
receptor and HER2 status, we found that severe obesity,
but not obesity, emerged as a statistically and clinically
significant unfavorable prognostic factor regardless of
BC subtype. These findings support further basic and
clinical research on the mechanisms of the association
between severe obesity and survival outcomes in BC pa-
tients in order to maximize treatment benefits among
these patients.
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